Details of the Drug

General Information of Drug (ID: DM9UB0P)

Drug Name
Oxaprozin
Synonyms
Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Approved [1]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 293.3
Topological Polar Surface Area (xlogp) 4.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
98% of drug becomes completely available to its intended biological destination(s) [3]
Elimination
0.5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 54.9 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 88.6374 micromolar/kg/day [6]
Vd
The volume of distribution (Vd) of drug is 11-17 L [7]
Water Solubility
The ability of drug to dissolve in water is measured as 1.7 mg/mL [2]
Chemical Identifiers
Formula
C18H15NO3
IUPAC Name
3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
Canonical SMILES
C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
InChI
InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
InChIKey
OFPXSFXSNFPTHF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4614
ChEBI ID
CHEBI:7822
CAS Number
21256-18-8
DrugBank ID
DB00991
TTD ID
D0M9DC
INTEDE ID
DR1212
ACDINA ID
D00498

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase (COX) TTK0943 PGH1_HUMAN; PGH2_HUMAN Inhibitor [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxaprozin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Oxaprozin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [29]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Oxaprozin and Glibenclamide. Acute diabete complication [5A2Y] [30]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Oxaprozin and Glipizide. Acute diabete complication [5A2Y] [30]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Oxaprozin and Inotersen. Amyloidosis [5D00] [31]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Oxaprozin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [32]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Oxaprozin and Cilostazol. Arterial occlusive disease [BD40] [33]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Oxaprozin and Budesonide. Asthma [CA23] [34]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Oxaprozin and Ofloxacin. Bacterial infection [1A00-1C4Z] [35]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Oxaprozin and Kanamycin. Bacterial infection [1A00-1C4Z] [36]
Sparfloxacin DMB4HCT Moderate Additive CNS stimulant effects by the combination of Oxaprozin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [35]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Oxaprozin and Streptomycin. Bacterial infection [1A00-1C4Z] [36]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Oxaprozin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [35]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Oxaprozin and Norfloxacin. Bacterial infection [1A00-1C4Z] [35]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Oxaprozin and ABT-492. Bacterial infection [1A00-1C4Z] [35]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Oxaprozin and Etidronic acid. Bone paget disease [FB85] [37]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Oxaprozin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [38]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Oxaprozin and Iodipamide. Cholelithiasis [DC11] [39]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Oxaprozin and Levomilnacipran. Chronic pain [MG30] [40]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Oxaprozin and Regorafenib. Colorectal cancer [2B91] [31]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Oxaprozin and Drospirenone. Contraceptive management [QA21] [41]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Oxaprozin and Ardeparin. Coronary thrombosis [BA43] [42]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Oxaprozin and Danaparoid. Deep vein thrombosis [BD71] [42]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Oxaprozin and Rivaroxaban. Deep vein thrombosis [BD71] [43]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Oxaprozin and Sertraline. Depression [6A70-6A7Z] [40]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Oxaprozin and Vilazodone. Depression [6A70-6A7Z] [40]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Oxaprozin and Vortioxetine. Depression [6A70-6A7Z] [40]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Oxaprozin and Milnacipran. Depression [6A70-6A7Z] [40]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Oxaprozin and Escitalopram. Depression [6A70-6A7Z] [40]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Oxaprozin and Desvenlafaxine. Depression [6A70-6A7Z] [40]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Oxaprozin and Clomipramine. Depression [6A70-6A7Z] [40]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Oxaprozin and Cannabidiol. Epileptic encephalopathy [8A62] [31]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Oxaprozin and Tazemetostat. Follicular lymphoma [2A80] [33]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Oxaprozin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [31]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Oxaprozin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [44]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Oxaprozin and Mipomersen. Hyper-lipoproteinaemia [5C80] [45]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Oxaprozin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [46]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Oxaprozin and BMS-201038. Hyper-lipoproteinaemia [5C80] [47]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Oxaprozin when combined with Trichlormethiazide. Hypertension [BA00-BA04] [48]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Oxaprozin and Balsalazide. Indeterminate colitis [DD72] [49]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Oxaprozin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [50]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Oxaprozin and Idelalisib. Mature B-cell leukaemia [2A82] [51]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Oxaprozin and Acalabrutinib. Mature B-cell lymphoma [2A85] [52]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Oxaprozin and Ibrutinib. Mature B-cell lymphoma [2A85] [53]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Oxaprozin and Ponatinib. Mature B-cell lymphoma [2A85] [54]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Oxaprozin and Exjade. Mineral absorption/transport disorder [5C64] [55]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Oxaprozin and Panobinostat. Multiple myeloma [2A83] [29]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Oxaprozin and Deflazacort. Muscular dystrophy [8C70] [34]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Oxaprozin and Dasatinib. Myeloproliferative neoplasm [2A20] [56]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Oxaprozin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [57]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Oxaprozin and Prasugrel. Myocardial infarction [BA41-BA43] [31]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Oxaprozin and Vorapaxar. Myocardial infarction [BA41-BA43] [58]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Oxaprozin and Sibutramine. Obesity [5B80-5B81] [40]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Oxaprozin and Dexfenfluramine. Obesity [5B80-5B81] [40]
Polythiazide DMCH80F Moderate Antagonize the effect of Oxaprozin when combined with Polythiazide. Oedema [MG29] [48]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Oxaprozin and MK-4827. Ovarian cancer [2C73] [31]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Oxaprozin and Epoprostenol. Pulmonary hypertension [BB01] [59]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Oxaprozin and Iloprost. Pulmonary hypertension [BB01] [59]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Oxaprozin and Everolimus. Renal cell carcinoma [2C90] [60]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Oxaprozin and Temsirolimus. Renal cell carcinoma [2C90] [60]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Oxaprozin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [35]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Oxaprozin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [31]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Oxaprozin and Pitolisant. Somnolence [MG42] [31]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Oxaprozin and Caplacizumab. Thrombocytopenia [3B64] [33]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Oxaprozin and Apixaban. Thrombosis [DB61-GB90] [31]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Oxaprozin and Cangrelor. Thrombosis [DB61-GB90] [33]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Oxaprozin and Brilinta. Thrombosis [DB61-GB90] [31]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Oxaprozin and Cabozantinib. Thyroid cancer [2D10] [61]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Oxaprozin and Tolbutamide. Type 2 diabetes mellitus [5A11] [30]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Oxaprozin and Olsalazine. Ulcerative colitis [DD71] [49]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Oxaprozin and Plazomicin. Urinary tract infection [GC08] [36]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Oxaprozin and Betrixaban. Venous thromboembolism [BD72] [62]
⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Quinoline yellow WS E00309 24671 Colorant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Oxaprozin 600 mg tablet 600 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
9 Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. J Clin Pharmacol. 1997 Apr;37(4):267-78.
10 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
11 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
12 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
13 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
15 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
16 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
17 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
18 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
19 Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
20 Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
21 Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
22 Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
23 Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
24 Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
25 Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
26 The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
27 Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
28 Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15.
29 Cerner Multum, Inc. "Australian Product Information.".
30 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
31 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
32 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
33 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
34 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
35 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
36 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
37 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
38 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
39 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
40 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
41 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
42 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
43 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
44 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
45 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
46 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
47 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
48 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
49 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
50 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
51 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
52 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
53 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
54 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
55 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
56 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
57 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
58 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
59 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
60 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
61 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
62 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.